Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)

Next Previous
Search
Trial Profile

A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary) ; Asparaginase; Blinatumomab; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocyte colony-stimulating factors; Idarubicin; Imatinib; Mercaptopurine; Methotrexate; Methotrexate; Methylprednisolone acetate; Prednisone; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms GRAALL-2014; GRAAPH2014

    • Most Recent Events

    • 10 Dec 2024 Results presented at the 66th American Society of Hematology Annual Meeting and Exposition
    • 10 Dec 2024 Planned number of patients changed from 265 to 743.
    • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top